Unlock stock picks and a broker-level newsfeed that powers Wall Street.

GlobeNewswire
OBI Pharma Announces Poster Presentations at the AACR 2025 Annual Meeting for OBI-992 and OBI-902 Antibody-Drug Conjugates (ADCs), GlycOBI® and ThiOBI® ADC enabling technologies, the OBI-3424 prodrug, and Globo H (GH) science
OBI Pharma Inc.
10 min read

In This Article:

OBI Pharma Inc.
OBI Pharma Inc.

Poster Presentations featuring the latest advancements on anti-TROP2 ADCs (OBI 992 and OBI 902), AKR1C3 prodrug (OBI-3424), OBI’s novel ADC enabling technologies (GlycOBI® and ThiOBI®), and Globo H science

TAIPEI, Taiwan, April 23, 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (TPEx: 4174. TWO) today announced nonclinical data for OBI-902, a potential best-in-class anti-TROP2 ADC developed using the next generation proprietary GlycOBI® technologies. OBI-902 demonstrated superior antitumor activity and favorable PK/PD properties compared to benchmark TROP2 ADCs across various animal models. OBI-992, a cysteine-based TROP2 targeting ADC, demonstrated a differentiated resistance profile compared to benchmark ADCs. Additionally, characterization and non-clinical in vivo data will be presented for the glycan-specific GlycOBI® and cysteine-based ThiOBI® proprietary ADC platforms, highlighting enhanced antitumor activity and stability in animal model studies. ThiOBI® is a new next-generation platform and adds to OBI’s armamentarium of ADC enabling technologies. Additionally, the non-clinical and antitumor activity of OBI-3424, a novel AKR1C3 targeted prodrug, will be presented. Furthermore, the potential correlation between GH expression and poor prognosis in cholangiocarcinoma (CCA), along with GH's role in modulating immune responses in CCA patients will be discussed.

These data will be presented at the American Association of Cancer Research (AACR) Annual Meeting from April 25 to 30, 2025 in Chicago, Illinois (USA).

“Our data demonstrated that OBI-902, derived from a site-specific GlycOBI® platform, showed favorable PK and differentiated profiles with good ADC stability in circulation, and efficient payload release in the tumor site of tumor bearing mouse. In the xenograft models, OBI-902 demonstrated both superior and more durable antitumor activity compared to benchmark ADCs. The GlycOBI® platform represents a breakthrough in antibody-drug conjugate (ADC) development as a distinct glycan site-specific technology, enabling a versatile drug-antibody ratio (DAR) and dual payload conjugations. The GlycOBI® platform consists of both EndoSymeOBI® enzyme and HYPrOBI™ linker technologies. The EndoSymeOBI® dual function enzyme technology enables a precise glycan remodeling for site-specific conjugation through a “one-pot” process. The HYPrOBI™ technology provides a masking effect to reduce payload hydrophobicity, while the shielding effect enhances controlled payload release, specifically in tumor environments to prevent premature release in circulation. Notably, this technology can achieve a drug-antibody ratio (DAR) as high as 16, which is the highest DAR that can be achieved in site-specific glycan platforms.” said OBI’s Chief Scientific Officer, Ming-Tain Lai, Ph.D. “Furthermore, the ThiOBI® platform was developed utilizing an irreversible cysteine conjugation alongside the HYPrOBI™ technology, to improve stability and prevents premature payload release. ADCs derived from the ThiOBI® platform demonstrated superior antitumor activity compared to traditional cysteine benchmark ADCs.”

Terms and Privacy Policy
Your Privacy Choices
Utah Privacy Notice
More Info

Recommended Stories